JP2022521591A5 - - Google Patents

Info

Publication number
JP2022521591A5
JP2022521591A5 JP2021549211A JP2021549211A JP2022521591A5 JP 2022521591 A5 JP2022521591 A5 JP 2022521591A5 JP 2021549211 A JP2021549211 A JP 2021549211A JP 2021549211 A JP2021549211 A JP 2021549211A JP 2022521591 A5 JP2022521591 A5 JP 2022521591A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
seq
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021549211A
Other languages
English (en)
Japanese (ja)
Other versions
JP7638215B2 (ja
JP2022521591A (ja
Filing date
Publication date
Priority claimed from GBGB1902419.9A external-priority patent/GB201902419D0/en
Application filed filed Critical
Publication of JP2022521591A publication Critical patent/JP2022521591A/ja
Publication of JP2022521591A5 publication Critical patent/JP2022521591A5/ja
Application granted granted Critical
Publication of JP7638215B2 publication Critical patent/JP7638215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021549211A 2019-02-22 2020-02-21 腎障害の治療 Active JP7638215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902419.9 2019-02-22
GBGB1902419.9A GB201902419D0 (en) 2019-02-22 2019-02-22 Treatment of kidney injury
PCT/EP2020/054580 WO2020169783A1 (en) 2019-02-22 2020-02-21 Treatment of kidney injury

Publications (3)

Publication Number Publication Date
JP2022521591A JP2022521591A (ja) 2022-04-11
JP2022521591A5 true JP2022521591A5 (cg-RX-API-DMAC7.html) 2023-02-14
JP7638215B2 JP7638215B2 (ja) 2025-03-03

Family

ID=65998854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549211A Active JP7638215B2 (ja) 2019-02-22 2020-02-21 腎障害の治療

Country Status (15)

Country Link
US (3) US11339216B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927742A1 (cg-RX-API-DMAC7.html)
JP (1) JP7638215B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210144708A (cg-RX-API-DMAC7.html)
CN (1) CN113748131A (cg-RX-API-DMAC7.html)
AU (1) AU2020224346B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016613A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130027A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002212A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191988A1 (cg-RX-API-DMAC7.html)
GB (1) GB201902419D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021010025A (cg-RX-API-DMAC7.html)
PH (1) PH12021552024A1 (cg-RX-API-DMAC7.html)
TW (2) TWI923323B (cg-RX-API-DMAC7.html)
WO (1) WO2020169783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
EP4260859A4 (en) * 2020-12-11 2024-05-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. USE OF A JAK INHIBITOR IN KIDNEY DISEASE
WO2023023473A1 (en) * 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
CN113960302B (zh) * 2021-09-29 2024-04-23 中国人民解放军军事科学院军事医学研究院 一种基于高内涵技术的肾毒性检测方法及其应用
WO2023086651A1 (en) * 2021-11-11 2023-05-19 Laboratory Corporation Of America Holdings Predicting a diagnostic test result from patient laboratory testing history
US20250082608A1 (en) * 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法
JP7457429B1 (ja) 2022-05-20 2024-03-28 学校法人藤田学園 腎障害の治療方法または予防方法において使用するための医薬組成物および当該医薬組成物を含む併用薬、並びに、ccbl1阻害剤
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
CN119367506B (zh) * 2024-10-14 2026-07-14 核工业总医院 一种用于治疗肾脏纤维化的药物及其应用
CN119548507A (zh) * 2024-11-12 2025-03-04 安徽医科大学 5-甲基四氢叶酸在制备治疗肾脏纤维化的药物中的应用
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
NZ574028A (en) * 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
CN108210909A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂质肾损伤的药物及其用途
CN108210893A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肾纤维化的药物及其用途
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
US20200031920A1 (en) * 2017-04-04 2020-01-30 The George Washington University Combination Therapy for Treating Cancer
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury

Similar Documents

Publication Publication Date Title
JP2022531591A5 (cg-RX-API-DMAC7.html)
Ge et al. Biology of interleukin-17 and its pathophysiological significance in sepsis
Li et al. The role of interleukins in colorectal cancer
Roy et al. Chemokines and chemokine receptors: update on utility and challenges for the clinician
Steeland et al. A new venue of TNF targeting
Jähnichen et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells
AU2023266285A1 (en) Interleukin-18 variants and methods of use
JP2020510662A5 (cg-RX-API-DMAC7.html)
US11046773B2 (en) Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
TW202037605A (zh) 腎損傷之治療
Villaescusa et al. A new approach to the management of COVID-19. Antagonists of IL-6: Siltuximab
TWI858005B (zh) 肝毒性之治療
US11059906B2 (en) Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
JP2022518251A5 (cg-RX-API-DMAC7.html)
CN111542546A (zh) 抗lag-3 抗体及其用途
TW200902064A (en) Methods and compositions for modulating IL-17F/IL-17A biological activity
JP2013504603A5 (cg-RX-API-DMAC7.html)
JP2023532272A5 (cg-RX-API-DMAC7.html)
Jöhrer et al. Tumour-immune cell interactions modulated by chemokines
KR20160133479A (ko) 자가면역 질환의 치료를 위한 조합 요법
Moreno et al. Role of chemokines in proteinuric kidney disorders
JP2022542443A5 (cg-RX-API-DMAC7.html)
Anderson et al. Interleukin-12 to interleukin ‘infinity’: the rationale for future therapeutic cytokine targeting
Gouraud et al. Down-regulation of chemokine Ccl5 gene expression in the NTS of SHR may be pro-hypertensive
US20240117053A1 (en) Clec12a antibody fragment sequences and methods